Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28-day studies

Environmental and Molecular Mutagenesis

Volumn 56, Issue 3, 2015, Pages 322-332

  Coffing, Stephanie L ^a   Kenyon, Michelle O ^a   Ackerman, Joel I ^a   Shutsky, Thomas J ^a   Dobo, Krista L ^a  

^a PFIZER INC   (United States)

Author keywords

Alkylating agent; Impurities; In vivo genotoxicity; In vivo mutation assay; Pig a mutation assay

Indexed keywords

ALKYL ESTER; ALKYLATING AGENT; ISOPROPYL METHANESULFONATE; MESYLIC ACID ETHYL ESTER; MUTAGENIC AGENT; UNCLASSIFIED DRUG; CD59 ANTIGEN; ISOPROPYLMETHANESULFONATE; MEMBRANE PROTEIN; MESYLIC ACID DERIVATIVE; PHOSPHATIDYLINOSITOL GLYCAN-CLASS A PROTEIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE; GENOTOXICITY; IN VIVO STUDY; MALE; MUTAGENICITY; MUTANT; MUTATION; NONHUMAN; PHENOTYPE; RAT; RETICULOCYTE; TOXICITY TESTING; WISTAR HANNOVER RAT; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; MICRONUCLEUS TEST; MUTAGEN TESTING; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PROCEDURES; WISTAR RAT;

RATTUS; SUIDAE;

ANIMALS; ANTIGENS, CD59; ERYTHROCYTES; MALE; MEMBRANE PROTEINS; MESYLATES; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; MUTAGENS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RATS, WISTAR; RETICULOCYTES;

EID: 84925301112     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21910     Document Type: Article

References (45)

1. ICoH (ICH). 2011. ICH Q3C Impurities: Guidelines for Residual Solvents (R5). pp 29. Available at: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf.
2. Adler ID, Tinwell H, Kliesch U, Ashby J. 1996. Activity of iPMS and nPMS in mouse bone marrow micronucleus assays: comparison with mouse dominant lethal assay data. Mutat Res 349:241-247.
3. Beranek DT. 1990. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 231:11-30.
4. Boysen G, Pachkowski BF, Nakamura J, Swenberg JA. 2009. The formation and biological significance of N7-guanine adducts. Mutat Res 678:76-94.
5. Bryce SM, Bemis JC, Dertinger SD. 2008. In vivo mutation assay based on the endogenous Pig-a locus. Environ Mol Mutagen 49:256-264.
6. Cammerer Z, Bhalli JA, Cao X, Coffing SL, Dickinson D, Dobo KL, Dobrovolsky VN, Engel M, Fiedler RD, Gunther WC, Heflich RH, Pearce MG, Shaddock JG, Shutsky T, Thiffeault CJ, Schuler M. 2011. Report on stage III Pig-a mutation assays using N-ethyl-N-nitrosourea-comparison with other in vivo genotoxicity endpoints. Environ Mol Mutagen 52:721-730.
7. Dertinger SD, Bryce SM, Phonethepswath S, Avlasevich SL. 2011a. When pigs fly: immunomagnetic separation facilitates rapid determination of Pig-a mutant frequency by flow cytometric analysis. Mutat Res 721:163-170.
8. Dertinger SD, Phonethepswath S, Avlasevich SL, Torous DK, Mereness J, Bryce SM, Bemis JC, Bell S, Weller P, Macgregor JT. 2012. Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds. Toxicol Sci 130:328-348.
9. Dertinger SD, Phonethepswath S, Franklin D, Weller P, Torous DK, Bryce SM, Avlasevich S, Bemis JC, Hyrien O, Palis J, MacGregor JT. 2010. Integration of mutation and chromosomal damage endpoints into 28-day repeat dose toxicology studies. Toxicol Sci 115:401-411.
10. Dertinger SD, Phonethepswath S, Weller P, Avlasevich S, Torous DK, Mereness JA, Bryce SM, Bemis JC, Bell S, Portugal S, Aylott M, MacGregor JT. 2011b. Interlaboratory Pig-a gene mutation assay trial: Studies of 1, 3-propane sultone with immunomagnetic enrichment of mutant erythrocytes. Environ Mol Mutagen 52:748-755.
11. Dertinger SD, Phonethepswath S, Weller P, Nicolette J, Murray J, Sonders P, Vohr HW, Shi J, Krsmanovic L, Gleason C, Custer L, Henwood A, Sweder K, Stankowski LF Jr, Roberts DJ, Giddings A, Kenny J, Lynch AM, Defrain C, Nesslany F, van der Leede BJ, Van Doninck T, Schuermans A, Tanaka K, Hiwata Y, Tajima O, Wilde E, Elhajouji A, Gunther WC, Thiffeault CJ, Shutsky TJ, Fiedler RD, Kimoto T, Bhalli JA, Heflich RH, MacGregor JT. 2011c. International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratories. Environ Mol Mutagen 52:690-698.
12. Doak SH, Jenkins GJ, Johnson GE, Quick E, Parry EM, Parry JM. 2007. Mechanistic influences for mutation induction curves after exposure to DNA-reactive carcinogens. Cancer Res 67:3904-3911.
13. Dobo KL, Fiedler RD, Gunther WC, Thiffeault CJ, Cammerer Z, Coffing SL, Shutsky T, Schuler M. 2011. Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats. Mutat Res 725:13-21.
14. Elder D, Facchine KL, Levey JN, Parsons R, Ridge D, Semo L, Teasdale A. 2012. An approach to control strategies for sulfonate ester formation in pharmaceutical manufacturing based on recent scientific understanding. Org Process Dev 16:1707-1710.
15. EMA. 2006. Evaluation of Medicines for Human Use: Guideline on the Limits of Genotoxic Impurities. London, England: EMA.
16. Glowienke S, Frieauff W, Allmendinger T, Martus HJ, Suter W, Mueller L. 2005. Structure-activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters. Mutat Res 581:23-34.
17. Gocke E, Ballantyne M, Whitwell J, Muller L. 2009. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU. Toxicol Lett 190:286-297.
18. Hemminki K. 1983. Nucleic acid adducts of chemical carcinogens and mutagens. Arch Toxicol 52:249-285.
19. Hemminki K, Koskinen M, Rajaniemi H, Zhao C. 2000. DNA adducts, mutations, and cancer 2000. Regul Toxicol Pharmacol 32:264-275.
20. Johnson GE, Soeteman-Hernandez LG, Gollapudi BB, Bodger OG, Dearfield KL, Heflich RH, Hixon JG, Lovell DP, Macgregor JT, Pottenger LH, Thompson CM, Abraham L, Thybaud V, Tanir JY, Zeiger E, van Benthem J, White PA. 2014. Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment. Environ Mol Mutagen. DOI 10.1002/em.21870.
21. La DK, Swenberg JA. 1996. DNA adducts: biological markers of exposure and potential applications to risk assessment. Mutat Res 365:129-146.
22. Lawley PD, Orr DJ, Jarman M. 1975. Isolation and identification of products from alkylation of nucleic acids: ethyl- and isopropyl-purines. Biochem J 145:73-84.
23. Lettell R, Milken GA, Stroup WW, Wolfinger RD. 2006. A Setting for Mixed Models Applications: Randomized Blocks Designs. SAS for Mixed Models. Cary, NC: SAS Inst Inc. pp 18-56.
24. Levene H. 1960. Robust test for equality of variances.In: Olkin I, Ghurye SG, Hoefding W, Madow WG, Mann HB, editors. Contributions to Probability and Statistics: Essays in Honor of Harold Hotelling. Stanford, CA: Stanford University Press. pp 278-292.
25. Li F, Solomon JJ, Mukai F, Segal A. 1990. In vitro reactions of isopropyl methanesulfonate with DNA and with 2'-deoxyribonucleosides. Cancer Biochem Biophys 11:253-264.
26. Lutz WK, Lutz RW. 2009. Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data. Mutat Res 678:118-122.
27. Lynch AM, Giddings A, Custer L, Gleason C, Henwood A, Aylott M, Kenny J. 2011. International Pig-a gene mutation assay trial (stage III): results with N-methyl-N-nitrosourea. Environ Mol Mutagen 52:699-710.
28. Mattison JD, Penrose LB, Burlinson B. 1997. Preliminary results of ethylnitrosourea, isopropyl methanesulphonate and methyl methanesulphonate activity in the testis and epididymal spermatozoa of Muta Mice. Mutat Res 388:123-127.
29. Miura D, Dobrovolsky VN, Kimoto T, Kasahara Y, Heflich RH. 2009. Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single and split doses of N-ethyl-N-nitrosourea. Mutat Res 677:86-92.
30. Miura D, Dobrovolsky VN, Kasahara Y, Katsuura Y, Heflich RH. 2008. Development of an in vivo gene mutation assay using the endogenous Pig-A gene: I. Flow cytometric Detection of CD59-Negative Peripheral Red Blood Cells and CD48-Negative Spleen T-Cells from the rat. Environ Mol Mutagen 49:614-621.
31. Morimoto K, Dolan ME, Scicchitano D, Pegg AE. 1985. Repair of O6-propylguanine and O6-butylguanine in DNA by O6-alkylguanine-DNA alkyltransferases from rat liver and E. coli. Carcinogenesis 6:1027-1031.
32. Muller L, Gocke E. 2009. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate. Toxicol Lett 190:330-332.
33. Pegg AE, Dolan ME, Scicchitano D, Morimoto K. 1985. Studies of the repair of O6-alkylguanine and O4-alkylthymine in DNA by alkyltransferases from mammalian cells and bacteria. Environ Health Perspect 62:109-114.
34. Peruzzi B, Araten DJ, Notaro R, Luzzatto L. 2010. The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivo. Mutat Res 705:3-10.
35. Phonethepswath S, Franklin D, Torous DK, Bryce SM, Bemis JC, Raja S, Avlasevich S, Weller P, Hyrien O, Palis J, Macgregor JT, Dertinger SD. 2010. Pig-a mutation: kinetics in rat erythrocytes following exposure to five prototypical mutagens. Toxicol Sci 114:59-70.
36. Provost GS, Rogers BJ, Dycaico MJ, Carr G. 1997. Evaluation of the transgenic Lambda/LacI mouse model as a short-term predictor of heritable risk. Mutat Res 388:129-136.
37. Sega GA, Owens JG, Cumming RB. 1976. Studies on DNA repair in early spermatid stages of male mice after in vivo treatment with methyl-, ethyl-, propyl-, and isopropyl methanesulfonate. Mutat Res 36:193-212.
38. Shelby MD, Tindall KR. 1997. Mammalian germ cell mutagenicity of ENU, IPMS and MMS, chemicals selected for a transgenic mouse collaborative study. Mutat Res 388:99-109.
39. Singer B. 1985. In vivo formation and persistence of modified nucleosides resulting from alkylating agents. Environ Health Perspect 62:41-48.
40. Swain C, Scott CB. 1953. Quantitative correlation of relative rates. Comparison of hydroxide ion with other nucleophilic reagents toward alkyl halides, esters, epoxides and acyl halides. J Am Chem Soc 75:141-147.
41. Tinwell H, Lefevre P, Williams CV, Ashby J. 1997. The activity of ENU, iPMS and MMS in male mouse germ cells using the Muta Mouse positive selection transgenic mutation assay. Mutat Res 388:179-185.
42. Torous DK, Phonethepswath S, Avlasevich SL, Mereness J, Bryce SM, Bemis JC, Weller P, Bell S, Gleason C, Custer LL, MacGregor JT, Dertinger SD. 2012. In vivo flow cytometric Pig-a and micronucleus assays: highly sensitive discrimination of the carcinogen/noncarcinogen pair benzo(a)pyrene and pyrene using acute and repeated-dose designs. Environ Mol Mutagen 53:420-428.
43. Vilarino-Guell C, Smith AG, Dubrova YE. 2003. Germline mutation induction at mouse repeat DNA loci by chemical mutagens. Mutat Res 526:63-73.
44. Vogel EW, Ashby J. 1994. Structure-activity relationships: Experimental approaches. Scope 52:231-254.
45. Vogel EW, Barbin A, Nivard MJ, Bartsch H. 1990. Nucleophilic selectivity of alkylating agents and their hypermutability in Drosophila as predictors of carcinogenic potency in rodents. Carcinogenesis 11:2211-2217.